Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Novo Holdings
Biotech
Backed by top VCs, biotech bags Alzheimer’s med in $2.2B deal
QuantumCell has committed $2.2 billion in milestones for a potentially symptom-relieving Alzheimer’s drug candidate that is on the cusp of phase 2.
Nick Paul Taylor
Jul 1, 2026 4:40am
Ray shines a light on $125M round targeting genetic eye therapy
Apr 21, 2026 10:33am
'Can it deliver?': Why Big Pharma has entered the quantum realm
Apr 10, 2026 7:20am
Novo Holdings assets shrink by 3rd as Novo Nordisk shares fall
Mar 12, 2026 7:15am
European VCs join forces to boost regional biotech investment
Feb 12, 2026 5:00am
JPM26: All of the meetings, none of the megadeals
Jan 15, 2026 4:30am
